Axonyx Inc., of New York, named to its board of directors Barry Cohen, former senior vice president of Merck & Co.

Biogen Inc., of Cambridge, Mass., named John Palmer vice president, program management.

BioMarin Pharmaceutical Inc., of Novato, Calif., named Raymond "Bill" Anderson chief operating officer.

Biosyn Inc., of Philadelphia, named Michael O'Brien vice president and chief financial officer, and Richard Bax vice president and chief scientific officer.

Chromos Molecular Systems Inc., of Burnaby, British Columbia, appointed to its board of directors Darrell Elliott, senior vice president of MDS Capital Corp. It also named Tom Marnic vice president, finance and chief financial officer.

Coulter Pharmaceutical Inc., of South San Francisco, appointed to its board of directors Samuel Saks, an oncologist.

Demegen Inc., of Pittsburgh, named Robert Fatora chief operating officer, pharmaceutical products.

Diamyd Medical AB, of Stockholm, Sweden, named to its scientific and medical advisory board Marco Londei, a professor of medicine and immunology at the Imperial College School of Medicine in London.

Discovery Technologies Ltd., of San Diego, and Allschwil, Switzerland, named Greg Sabbatini director of business development and marketing North America, and Annette Brandt marketing manager Europe.

Eligix Inc., of Medford, Mass., named Tara Clark vice president of global marketing.

Gambro AB, of Stockholm, Sweden, appointed Larry Buckelew president, Gambro Healthcare US.

Immunex Corp., of Seattle, promoted Michael Kirschner to vice president, intellectual property.

Kinetek Pharmaceuticals Inc., of Vancouver, British Columbia, named James Hudson senior vice president, finance and administration, and chief financial officer.

Maxygen Inc., of Redwood City, Calif., promoted Simba Gill to president.

Morphochem AG, of Munich, Germany, appointed Stephanie Plassmann head of preclinical development.

Novavax Inc., of Columbia, Md., named James Mirto senior vice president and chief operating officer.

Organogenesis Inc., of Canton, Mass., named John Arcari chief financial officer, as well as vice president, finance and administration, secretary and treasurer.

Oxagen Ltd., of Oxford, UK, appointed Christine Soden chief financial officer.

Pheromone Sciences Corp., of Toronto, named Barry Sadrehashemi chief financial officer. In addition, it elected to its board of directors Andrew Saxton, deputy chairman of Allied Hotel Properties Inc.

PowderJect Pharmaceuticals plc, of Fremont, Calif., and Oxford, UK, named Juan Harrison senior director business development, and Rhoda Sjoberg director of marketing.

Protein Polymer Technologies Inc., of San Diego, elected to its board of directors Kerry Kuhn, a board-certified gynecologist.

Raven Biotechnologies Inc., of San Carlos, Calif., named Gordon Vehar vice president, research and development, and Donald Perryman vice president and chief business officer.

Rigel Pharmaceuticals Inc., of South San Francisco, appointed Raul Rodriquez vice president, business development.

Sangamo BioSciences Inc., of Point Richmond, Calif., named to its board of directors Jon Jacoby, executive vice president of Stephens Group Inc.

Sunesis Pharmaceuticals Inc., of Redwood City, Calif., named Daryl Winter senior vice president and general counsel.

Targeted Genetics Corp., of Seattle, named Alison Heald program physician; B.G. Susan Primrose director, business development; David Schubert senior director, strategic initiatives; and Stephanie Seiler director, communications.

Transkaryotic Therapies Inc., of Cambridge, Mass., named to its board of directors Nobel Laureate Walter Gilbert, a professor at Harvard University.

ZymeTx Inc., of Oklahoma City, named to its board of directors Rand Mulford, managing director at Spencer Trask Securities Inc.